These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21576578)

  • 1. Endothelial damage in all types of T-lymphocyte-mediated drug-induced eruptions.
    Verneuil L; Leboeuf C; Vidal JS; Ratajczak P; Comoz F; Ameisen JC; Janin A
    Arch Dermatol; 2011 May; 147(5):579-84. PubMed ID: 21576578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cell apoptosis in severe drug-induced bullous eruptions.
    Verneuil L; Ratajczak P; Allabert C; Leboeuf C; Comoz F; Janin A; Ameisen JC
    Br J Dermatol; 2009 Dec; 161(6):1371-5. PubMed ID: 19575754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
    Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
    Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity.
    Hanafusa T; Azukizawa H; Matsumura S; Katayama I
    J Dermatol Sci; 2012 Mar; 65(3):213-9. PubMed ID: 22226608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests.
    Kanny G; Pichler W; Morisset M; Franck P; Marie B; Kohler C; Renaudin JM; Beaudouin E; Laudy JS; Moneret-Vautrin DA
    J Allergy Clin Immunol; 2005 Jan; 115(1):179-85. PubMed ID: 15637566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
    Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
    Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell involvement in drug-induced acute generalized exanthematous pustulosis.
    Britschgi M; Steiner UC; Schmid S; Depta JP; Senti G; Bircher A; Burkhart C; Yawalkar N; Pichler WJ
    J Clin Invest; 2001 Jun; 107(11):1433-41. PubMed ID: 11390425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical heterogeneity of drug hypersensitivity.
    Roujeau JC
    Toxicology; 2005 Apr; 209(2):123-9. PubMed ID: 15767024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).
    Smith KJ; Skelton HG; Yeager J; Ledsky R; Ng TH; Wagner KF
    Clin Exp Dermatol; 1997 May; 22(3):118-23. PubMed ID: 9425690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases.
    Bellón T; Alvarez L; Mayorga C; Morel E; Torres MJ; Martín-Díaz MA; Díaz R; Radial A; Carballo M; Blanca M
    Br J Dermatol; 2010 May; 162(5):1014-22. PubMed ID: 20030638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced exanthems.
    Yawalkar N
    Toxicology; 2005 Apr; 209(2):131-4. PubMed ID: 15767025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug hypersensitivity reactions involving skin.
    Hausmann O; Schnyder B; Pichler WJ
    Handb Exp Pharmacol; 2010; (196):29-55. PubMed ID: 20020258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation.
    Meth MJ; Sperber KE
    Mt Sinai J Med; 2006 Sep; 73(5):769-76. PubMed ID: 17008937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug eruptions: approaching the diagnosis of drug-induced skin diseases.
    Nigen S; Knowles SR; Shear NH
    J Drugs Dermatol; 2003 Jun; 2(3):278-99. PubMed ID: 12848112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions.
    Morel E; Alvarez L; Cabañas R; Fiandor A; Díaz R; Escamochero S; Prior N; Blanca M; Bellón T
    Allergy; 2011 Mar; 66(3):360-7. PubMed ID: 20880148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas.
    Stur K; Karlhofer FM; Stingl G
    J Invest Dermatol; 2007 Apr; 127(4):802-7. PubMed ID: 17139262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine.
    Goh TK; Pang SM; Thirumoorthy T; Goh SG
    Singapore Med J; 2008 Jun; 49(6):507-10. PubMed ID: 18581028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study.
    Lage D; Juliano PB; Metze K; de Souza EM; Cintra ML
    Int J Dermatol; 2012 Oct; 51(10):1199-205. PubMed ID: 22416968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
    Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell populations propagating in the peripheral blood of patients with drug eruptions.
    Nishio D; Izu K; Kabashima K; Tokura Y
    J Dermatol Sci; 2007 Oct; 48(1):25-33. PubMed ID: 17601705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.